Verinata Health announced that it is expanding the verifi prenatal test capabilities to include detection of the most common sex chromosome abnormalities. Clinicians will now have the ability to select the sex chromosomes option on the verifi test to access this addition.
The test offers a comprehensive non-invasive test to detect the most common chromosomal fetal abnormalities seen in pregnancy, including Down syndrome (trisomy 21 or T21), Edwards syndrome (trisomy 18 or T18) and Patau syndrome (trisomy 13 or T13). The optional expansion now includes detection of Turner syndrome (Monosomy X), Trisomy X (XXX), Klinefelter syndrome (XXY) and XYY syndrome, the most common fetal sex chromosome abnormalities. This test can also aid in the diagnosis of X-linked disorders (eg, hemophilia, Duchenne muscular dystrophy or cases of congenital adrenal hyperplasia).
The verifi prenatal test utilizes massively parallel sequencing (MPS) with a highly-optimized algorithm to provide results for chromosomes 21, 18, and 13 as well as the sex chromosomes.
This test expansion will be available beginning December 3, 2012.
For more information call (855) 266-6563 or visit www.verinata.com.